MaxCyte, Inc. Participation in Upcoming Investor Conferences
February 23 2021 - 2:00AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
22 February 2021
FOR IMMEDIATE RELEASE
MaxCyte to Participate in Two Upcoming Virtual Healthcare
Investor Conferences
GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global
cell-based therapies and life sciences company, today announced two
upcoming presentations at virtual healthcare investor conferences.
Details are as follows:
Cowen 41st Annual Health Care Conference
Who: Doug Doerfler, President & Chief Executive Officer, and
Amanda Murphy, Chief Financial Officer, will present a corporate
overview
Dates: Virtual conference March 1 - 4, 2021
MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET
An archived version of the presentation will be made available
following the conference in the Investors section of the Company
website
H.C. Wainwright & Co Global Life Sciences Conference
Who: Doug Doerfler, President & Chief Executive Officer,
will present a corporate overview
Dates: Virtual conference March 9 - 10, 2021
MaxCyte Presentation Details: Available on demand to conference
participants March 9 - 10, 2021
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering platform
technology and is responsible for helping to bring next--generation
cell and gene-editing therapies to life. The Company's technology
is deployed by leading drug developers worldwide, including all of
the top ten global biopharmaceutical companies. MaxCyte licenses
have been granted for more than 140 cell therapy programs, with
more than 100 licensed for clinical use, and the Company has now
entered into 12 clinical/commercial license partnerships with
leading cell therapy and gene editing developers. MaxCyte was
founded in 1998 and is headquartered in Gaithersburg, Maryland, US.
For more information, visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Amanda Murphy, Chief Financial
Officer +1 301-944-1660
Nominated Adviser and Joint
Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Brokers
Numis Securities Limited
James Black / Duncan Monteith /
Matthew O'Dowd +44 (0)20 7260 1000
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic +44 (0)203 709 5700
Communications maxcyte@consilium-comms.
Mary-Jane Elliott / Chris Welsh com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAEAAAALFEAA
(END) Dow Jones Newswires
February 23, 2021 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2023 to Aug 2024